摘要
类风湿关节炎(RA)是一种以滑膜炎及骨破坏为特征的全身炎症性自身免疫性疾病,若未及时治疗,最终会发展为关节畸形、功能障碍,甚至残疾。Janus激酶(JAK)转录活化子(STAT)信号通路在RA的发生发展中扮演关键角色,针对该通路的治疗靶点使RA疾病缓解成为现实,故成为近年来研究的热点。本文就JAK/STAT信号通路的结构与功能,对该通路参与RA滑膜炎症、软骨及骨侵蚀的作用机制进行阐释,总结基础实验和临床药物对该通路治疗靶点的最新研究成果,重点对目前全球批准的14种JAK抑制剂最新研究现状进行综述,为更多RA治疗药物的研发提供新思路。
Rheumatoid arthritis(RA)is a systemic inflammatory autoimmune disease characterized by synovitis and bone destruction.If it is not treated in time,it will eventually aggravate into joint deformity,dysfunction and even disability.The Janus kinase(JAK)signal transducer and activator of transcription(STAT)signaling pathway plays a key role in the occurrence and development of RA.Therapeutic targets based on the JAK/STAT signaling pathway for RA have shown the potential in relieving RA,which have been extensively analyzed in recent years.Based on the structure and function of the JAK/STAT signaling pathway,this papeRexplains the mechanism of the JAK/STAT signaling pathway in synovitis,cartilage and bone erosion in RA,summarizes the latest research results of basic experiments and clinical drugs on the therapeutic targets of the JAK/STAT signaling pathway,and focuses on the latest research status of 14 JAK inhibitors that have been approved worldwide.OuRfindings are expected to provide new ideas for the research and development of more therapeutic drugs for RA.
作者
许炬珍
张丽卿
XU Juzhen;ZHANG Liqing(Fenyang College of Shanxi Medical University,Shanxi,Fenyang 032200,China;不详)
出处
《河北医药》
CAS
2024年第4期601-605,611,共6页
Hebei Medical Journal
基金
吕梁市科技重点研发项目(编号:2018shfz65-7)
山西医科大学汾阳学院科技发展重点项目(编号:2019C07)
山西省汾阳医院科技攻关项目(编号:202008)。
关键词
类风湿关节炎
JAK/STAT信号通路
治疗靶点
JAK抑制剂
rheumatoid arthritis
Janus kinase(JAK)/signal transducer and activator of transcription(STAT)signaling pathway
therapeutic targets
Janus kinase(JAK)inhibitors
